Most Read Articles
Stephen Padilla, 12 Feb 2020
Increased coffee consumption appears to lower the risk of colon adenoma, results of a meta-analysis have shown. However, this association should be carefully considered due to latent confusion and different exposure classification.
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
01 Dec 2019
Pneumonia is a common infection– affecting around 3,200 people inSingapore in 2016 – making it the thirdmost common cause of hospitalisation inthe country. Its common complications,especially with delayed or inappropriatetreatment, include bacteraemia andseptic shock, lung abscesses, pleuraleffusions, empyema, pleurisy, respiratoryfailure and renal failure.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.

Ribociclib-fulvestrant combo improves PFS in HR+/HER2- advanced breast cancer

Elaine Soliven
03 Jul 2018

The combination of ribociclib, a CDK*4/6 inhibitor, and fulvestrant significantly improves progression-free survival (PFS) in post-menopausal women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer, according to the MONALEESA-3** study presented at ASCO 2018.

“Ribociclib and fulvestrant may represent a new therapeutic option in this subtype of advanced breast cancer, both for patients receiving treatment in the first-line … [and] second-line setting[s],” said lead author Dr Dennis J. Slamon from the University of California, Los Angeles (UCLA) Medical Center in Santa Monica, California, US.

This phase III, double-blind trial involved 726 post-menopausal women (median age 63 years) with HR+/HER2- advanced breast cancer who were randomized in a 2:1 ratio to receive oral ribociclib (600 mg/day on a 3-week-on, 1-week-off schedule) plus intramuscular fulvestrant (500 mg on day 1 of each 28-day cycle) or placebo plus fulvestrant (fulvestrant only group). Tumour response assessments were performed every 8 weeks for 18 months and subsequently every 12 weeks. [ASCO 2018, abstract 1000]

Compared with women who received fulvestrant only, women treated with ribociclib + fulvestrant had significantly improved PFS (210 vs 151 events; median, 20.5 vs 12.8 months, hazard ratio [HR], 0.593, 95 percent confidence interval [CI], 0.480– 0.732; p<0.001).

When 40 percent of the patients were randomly assessed by the BIRC***, results also showed improved PFS among women in the ribociclib + fulvestrant group over the fulvestrant only group (median, not reached vs 10.9 months, HR, 0.492, 95 percent CI, 0.345–0.703).

In a subgroup analysis of PFS by prior endocrine therapy status, a significantly better PFS rate was observed among women on ribociclib + fulvestrant compared with those on fulvestrant only in the first-line (defined as treatment naïve for advanced breast cancer; median PFS, not reached vs 18.3 months, HR, 0.577, 95 percent CI, 0.415–0.802) and second-line setting (defined as up to one line of prior endocrine therapy for advanced breast cancer; median PFS, 14.6 vs 9.1 months, HR, 0.565, 95 percent CI, 0.428–0.744).

The overall response and clinical benefit rates were also significantly higher among patients who received ribociclib + fulvestrant vs fulvestrant only (32.4 percent vs 21.5 percent; p<0.001 and 70.2 percent vs 62.8 percent; p=0.020, respectively), though these findings are still immature, said the researchers.

The most common non-haematologic all-grade adverse events reported in the ribociclib + fulvestrant vs fulvestrant only groups were nausea, fatigue, and diarrhoea (45.3 percent vs 28.2 percent, 31.5 percent vs 33.2 percent, and 29.0 percent vs 20.3 percent, respectively). Grade 3 and 4 febrile neutropenia only occurred among women in the ribociclib + fulvestrant group (46.6 percent and 6.8 percent, respectively), with no cases reported in the fulvestrant only group.

“The efficacy results seen here for treatment-naïve advanced disease as well as those from other studies of CDK4/6 inhibitors in HR+/HER2- breast cancer supports the study of ribociclib in early HR+/HER2- disease,” said Slamon.

“Additional analyses from the study may help further elucidate mechanisms of resistance to endocrine therapy and CDK4/6 inhibitors,” he added.

 

*CDK: Cyclin-dependent kinase

**MONALEESA-3: Study of efficacy and safety of LEE011 in men and postmenopausal women with advanced breast cancer

***BIRC: Blinded Independent Review Committee
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 12 Feb 2020
Increased coffee consumption appears to lower the risk of colon adenoma, results of a meta-analysis have shown. However, this association should be carefully considered due to latent confusion and different exposure classification.
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
01 Dec 2019
Pneumonia is a common infection– affecting around 3,200 people inSingapore in 2016 – making it the thirdmost common cause of hospitalisation inthe country. Its common complications,especially with delayed or inappropriatetreatment, include bacteraemia andseptic shock, lung abscesses, pleuraleffusions, empyema, pleurisy, respiratoryfailure and renal failure.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.